NUC-3373 + leucovorin

NUC-3373 + leucovorin is an investigational combination therapy for advanced solid tumors, particularly colorectal cancer. NUC-3373 is a novel phosphoramidate nucleotide analog of fluorodeoxyuridine (FUDR), designed to overcome the limitations of 5-fluorouracil (5-FU) by directly delivering the active anti-cancer metabolite fluorodeoxyuridine-monophosphate (FdUMP) intracellularly. This results in potent inhibition of thymidylate synthase, leading to DNA damage and cell death. Leucovorin (folinic acid) is co-administered to enhance the inhibition of thymidylate synthase by stabilizing the FdUMP-thymidylate synthase complex, thereby increasing anti-tumor efficacy. The combination aims to improve efficacy and reduce toxicities compared to standard 5-FU regimens. Developed primarily for use in patients with advanced or metastatic solid tumors who have relapsed after prior therapies, this regimen has shown promising early clinical activity and a favorable safety profile in heavily pre-treated populations[1][4][5][6][7][9].

Other names

NUFIRI (when combined with irinotecan and bevacizumab)